Search

Displaying results 41 - 50 of 332 in total
  1. Drug

    Levofloxacin

    go.drugbank.com/drugs/DB01137
    ApprovedInvestigational

    Levofloxacin is a fluoroquinolone antibiotic and the optical S-(-) isomer of racemic ofloxacin. It reportedly carries 8 to 128-fold more activity against both gram-negative and gram-positive bacteria compared to R-(+)-ofloxacin and remai...

    Products: LEVOFLOXACINA HETERO EUROPE
  2. Drug

    Ostrea edulis shell

    go.drugbank.com/drugs/DB14251
    Investigational

    Ostrea edulis shell is an animal extract used in some OTC (over-the-counter) products. It is not an approved drug.

    Synonyms: European Flat Oyster Shell
  3. Drug

    Sodium fluorophosphate

    go.drugbank.com/drugs/DB09484
    ApprovedInvestigational

    Sodium monofluorophosphate is used in OTC dental preparations to help protect against cavities.

    Products: Colgate Optic White Platinum Express White Fresh Mint
  4. Drug

    Axicabtagene ciloleucel

    go.drugbank.com/drugs/DB13915
    ApprovedInvestigational

    [A216163] Once T-cells are collected from the patient, they are genetically engineered to express anti-CD19 CARs that recognize and kill cancer cells, and are infused back into the patient.

  5. Drug

    Maralixibat

    go.drugbank.com/drugs/DB16226
    ApprovedInvestigational

    [L38834] Previously, patients with cholestatic pruritus associated with Alagille syndrome were treated with antihistamines, [rifampin], [ursodeoxycholic acid], [cholestyramine], [naltrexone], and [sertraline … Use (CHMP) recommended maralixibat be granted marketing authorization for the treatment of cholestatic pruritus in patients with Alagille syndrome:[L43547] it was granted marketing authorization in Europe

  6. Drug

    Idecabtagene vicleucel

    go.drugbank.com/drugs/DB16665
    ApprovedInvestigational

    [A232563] These cancerous cells generally express the B-cell maturation antigen, while it is rarely expressed on non-cancerous cells. … [A232558,A232563,L32858] These therapies involve extracting and genetically manipulating T-cells from a patient to express a CAR for a tumor specific antigen.

  7. Drug

    Methylnaltrexone

    go.drugbank.com/drugs/DB06800
    ApprovedInvestigational

    Methylnaltrexone is a pheriphally-acting μ-opioid antagonist that acts on the gastrointestinal tract to decrease opioid-induced constipation without producing analgesic effects or withdrawal symptoms. It is also a weak CYP2D6 inhibitor. ...

  8. Indication

    >1 weight-related comorbidity

    go.drugbank.com/conditions/DBCOND0106160
    Drugs: Naltrexone
  9. Indication

    Increased physical activity levels

    go.drugbank.com/conditions/DBCOND0026535
    Drugs: Naltrexone
  10. Drug

    Prademagene zamikeracel

    go.drugbank.com/drugs/DB17895
    ApprovedInvestigational

    [A273833,A273838] Patient cells are then transduced ex vivo with a replication-incompetent retroviral vector (RVV) containing the full-length COL7A1 gene, resulting in cells that express functional collagen